Author: kodiac

  • Polygalasaponin F

    Oleanane-type triterpenoid saponin with multi-target neuroprotective, anti-inflammatory, and cognition-enhancing activity

    An oleanane triterpenoid saponin isolated from Polygala japonica Houtt. with demonstrated neuroprotection against ischemic and excitotoxic injury, long-term potentiation enhancement via NMDA receptor activation, and anti-neuroinflammatory activity through TLR4-PI3K/AKT-NF-kB and TXNIP/NLRP3 pathway modulation.

    Abstract

    Polygalasaponin F (PGSF) is an oleanane-type triterpenoid saponin originally isolated from the aerial parts of Polygala japonica Houtt., a perennial herb of the Polygalaceae family used in traditional East Asian medicine for its sedative, expectorant, and cognition-enhancing properties. The compound has a molecular formula of C53H86O23 (molecular weight 1091.2 g/mol) and bears a presqualene-derived oleanane aglycone substituted with a 3-O-beta-D-glucopyranosyl unit and a C-28 ester-linked trisaccharide chain composed of glucopyranose, rhamnopyranose, and xylopyranose residues. PGSF has emerged as a compound of substantial preclinical research interest across multiple neuroprotective and anti-inflammatory domains, supported by a growing body of in vitro and in vivo evidence published principally between 2012 and 2025.

    The pharmacological profile of PGSF is characterized by multi-target activity converging on neuronal survival, synaptic plasticity, and neuroinflammatory suppression. In adult rat hippocampal slices, PGSF at 1 to 10 micromolar induces sustained long-term potentiation (LTP) in the dentate gyrus through activation of N-methyl-D-aspartate receptors (NMDARs), with downstream phosphorylation of NR2B, calcium/calmodulin-dependent protein kinase II (CaMKII), extracellular signal-regulated kinase (ERK), and cyclic AMP response element-binding protein (CREB), placing it among a small number of natural saponins with direct electrophysiological evidence of synaptic strengthening. In cultured hippocampal neurons exposed to glutamate excitotoxicity, PGSF produces concentration-dependent neuroprotection by attenuating cytosolic calcium overload and modulating NMDAR subunit expression, specifically preserving NR2A while limiting excess NR2B-mediated calcium influx. In oxygen-glucose deprivation and reoxygenation (OGD/R) models of ischemic injury using PC12 cells and primary cortical neurons, PGSF activates the PI3K/Akt survival signaling pathway, upregulates the Bcl-2/Bax ratio, and suppresses caspase-3 activation to inhibit apoptosis.

    The anti-inflammatory pharmacology of PGSF operates through at least two characterized signaling cascades. In lipopolysaccharide-stimulated BV-2 microglial cells, PGSF suppresses tumor necrosis factor alpha (TNF-alpha) release through inhibition of the toll-like receptor 4 (TLR4) to phosphoinositide 3-kinase (PI3K) to protein kinase B (AKT) to nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling axis. In middle cerebral artery occlusion (MCAO) rat models of focal ischemia and reperfusion, PGSF ameliorates neurological deficit, reduces infarct volume, and inhibits the thioredoxin-interacting protein (TXNIP) to NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome signaling pathway. More recent studies (2024 to 2025) have identified additional mechanistic targets: PGSF downregulates the Na-K-2Cl cotransporter 1 (NKCC1) through enhanced DNA methylation, thereby reducing blood-brain barrier disruption and cerebral edema following ischemia-reperfusion, and PGSF alleviates cerebral ischemia-reperfusion injury through inhibition of excessive mitophagy, preserving mitochondrial membrane potential and reducing mitochondrial reactive oxygen species accumulation.

    No clinical trials of PGSF in humans have been conducted. The compound remains in the preclinical investigational phase, with the entirety of the evidence base derived from in vitro cell culture systems and rodent models of cerebral ischemia, glutamate excitotoxicity, and neuroinflammation. Pharmacokinetic data specific to PGSF in any species are not available in published form; general considerations for triterpenoid saponin bioavailability (gastrointestinal hydrolysis of glycosidic bonds, limited oral absorption of intact saponin, hepatic first-pass metabolism) apply and represent a translational barrier that has not been formally addressed. The compound is available from multiple research chemical suppliers at greater than 95 percent purity for in vitro and in vivo research applications. This monograph reviews the chemistry, isolation, and structural characterization of PGSF; the multi-target molecular pharmacology across NMDA receptor, PI3K/Akt, TLR4/NF-kB, TXNIP/NLRP3, NKCC1, and mitophagy pathways; the preclinical evidence base in ischemic stroke, glutamate excitotoxicity, and neuroinflammation models; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse events and safety signals from animal studies; and a comparative assessment of five neuroprotective Polygala-derived saponins against PGSF on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1615Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Cebranopadol

    Mixed nociceptin/orphanin FQ peptide (NOP) receptor and opioid receptor agonist analgesic

    A first-in-class spiro-indole analgesic with near-equipotent agonism at nociceptin/orphanin FQ peptide and classical opioid receptors, developed by Grunenthal and advanced by Tris Pharma through Phase 3 acute pain trials, distinguished from conventional opioids by NOP receptor-mediated attenuation of respiratory depression and abuse liability.

    Abstract

    Cebranopadol (GRT-6005, PRK-101, TRN-228) is a first-in-class small-molecule analgesic that acts as a high-affinity agonist at the nociceptin/orphanin FQ peptide (NOP) receptor and at the three classical opioid receptor subtypes (mu, kappa, and delta), with near-equipotent activation of the NOP and mu-opioid receptors at low-nanomolar concentrations. The compound was discovered at Grunenthal GmbH in Aachen, Germany, and first described in patent literature in 2002. Scientific characterization beginning in 2013 established cebranopadol as a spiro[cyclohexane-dihydropyrano[3,4-b]indole] derivative with binding affinities (Ki) of 0.7 nM at the human mu-opioid receptor, 0.9 nM at the human NOP receptor, 2.6 nM at the kappa-opioid receptor, and 18 nM at the delta-opioid receptor, and with functional potencies (EC50) of 1.2 nM (mu), 13 nM (NOP), 17 nM (kappa), and 110 nM (delta) in calcium mobilization assays, yielding a rank order of potency mu approximately equal to NOP, then kappa, then delta. The compound acts as a full agonist at the mu-opioid and delta-opioid receptors, a near-full agonist at the NOP receptor (89 percent relative efficacy), and a partial agonist at the kappa-opioid receptor (67 percent relative efficacy). A distinctive signaling feature is G-protein bias at the NOP receptor, where cebranopadol promotes G-protein coupling without measurable beta-arrestin 2 recruitment, while retaining full beta-arrestin 2 coupling at the mu-opioid receptor.

    The dual NOP and opioid receptor agonism produces a pharmacological profile that is differentiated from conventional mu-selective opioid analgesics in three respects: (1) enhanced relative potency in models of chronic neuropathic and inflammatory pain compared with acute nociceptive pain, with a seven-fold potency advantage in the mouse formalin test relative to the tail-withdrawal paradigm; (2) attenuation of opioid-type respiratory depression, with preclinical evidence of a ceiling effect on respiratory suppression attributable to the NOP receptor contribution; and (3) reduced abuse liability, demonstrated in a Phase 1 human abuse potential study showing less drug-liking and lower subjective effects relative to hydromorphone in non-dependent recreational opioid users, and in a separate study showing less abuse potential than tramadol and oxycodone. Additionally, preclinical studies demonstrated delayed analgesic tolerance development (26 days in cebranopadol-treated animals versus 11 days for morphine at equianalgesic doses in the chronic constriction injury model).

    Pharmacokinetics in humans are characterized by complete oral absorption with approximately 40 percent bioavailability reflecting first-pass hepatic metabolism, a late time to maximum plasma concentration (4 to 6 hours), a long terminal elimination half-life of 62 to 96 hours, and an operational half-life of approximately 24 hours supporting once-daily dosing. Steady-state plasma concentrations are achieved after approximately two weeks of daily administration, with an accumulation factor of approximately 2-fold and low peak-trough fluctuation (70 to 80 percent). Clearance is influenced by CYP2C9 phenotype, with poor and intermediate metabolizers showing reduced clearance relative to extensive metabolizers. The compound does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 at concentrations up to 250 nM, indicating a low potential for metabolic drug-drug interactions.

    Clinical development has encompassed more than 32 clinical trials involving more than 2,200 participants. A Phase 2 randomized, double-blind, placebo-controlled and active-controlled (tapentadol) trial in chronic low back pain (Christoph et al. 2017) demonstrated statistically significant and clinically relevant analgesic efficacy at doses of 200, 400, and 600 micrograms once daily over 14 weeks. A Phase 2a trial in postoperative acute pain demonstrated efficacy at 400 and 600 microgram doses. Two pivotal Phase 3 trials (ALLEVIATE-1, in post-abdominoplasty pain, and ALLEVIATE-2, in post-bunionectomy pain) met their primary efficacy endpoints, with cebranopadol 400 micrograms demonstrating significant reduction in pain intensity versus placebo. The ALLEVIATE-2 trial additionally showed that a higher proportion of cebranopadol-treated patients required no opioid rescue medication compared with placebo. Tris Pharma, which acquired worldwide rights to cebranopadol through its 2021 acquisition of Park Therapeutics, has announced plans for FDA submission. The compound is not yet approved by any regulatory authority and is not a scheduled controlled substance as of 2025. This monograph reviews the chemistry, synthesis, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, handling, stack interactions, safety profile, and a comparative assessment of five analgesic candidates against cebranopadol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1597Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Mirogabalin

    Selective alpha-2-delta-1 subunit ligand of voltage-gated calcium channels (gabapentinoid)

    A next-generation gabapentinoid developed by Daiichi Sankyo with preferential binding and prolonged dissociation kinetics at the alpha-2-delta-1 subunit of voltage-gated calcium channels, approved in Japan and select Asian jurisdictions for peripheral neuropathic pain and distinguished from pregabalin and gabapentin by subunit selectivity and a potentially wider therapeutic margin.

    Abstract

    Mirogabalin (DS-5565) is a novel gabapentinoid analgesic that binds with high affinity and selectivity to the alpha-2-delta-1 (alpha2delta-1) subunit of voltage-gated calcium channels (VGCCs), developed by Daiichi Sankyo Company and approved in Japan in January 2019 for the treatment of peripheral neuropathic pain associated with diabetic peripheral neuropathy (DPNP) and postherpetic neuralgia (PHN). The compound is marketed as Tarlige in oral tablet formulation and has subsequently received regulatory approval in Taiwan (2020) and Thailand (2022) for peripheral neuropathic pain indications. Unlike the first-generation gabapentinoids gabapentin and pregabalin, which bind nonselectively to both alpha2delta-1 and alpha2delta-2 subunits with comparable affinity and dissociation kinetics, mirogabalin demonstrates preferential binding to the alpha2delta-1 subunit with a dissociation half-life of approximately 11.1 hours at alpha2delta-1 versus 2.4 hours at alpha2delta-2 in human recombinant systems. This kinetic selectivity is hypothesized to confer a favorable ratio of analgesic efficacy (mediated principally through alpha2delta-1 in dorsal root ganglia and spinal cord dorsal horn) to central nervous system adverse effects (mediated in part through alpha2delta-2 in cerebellar Purkinje neurons and other central structures), although this hypothesis has not been formally validated in controlled comparative clinical trials against pregabalin at equipotent analgesic doses.

    The clinical development program for mirogabalin comprises two pivotal Phase 3 randomized, double-blind, placebo-controlled trials in Asian patients with DPNP (834 patients) and PHN (765 patients), both of which demonstrated statistically significant reductions in average daily pain scores at week 14 relative to placebo across multiple dose groups (15 mg once daily, 10 mg twice daily, and 15 mg twice daily). A separate Phase 3 program evaluated mirogabalin for central neuropathic pain after spinal cord injury in a multinational Asian trial. In contrast, the global Phase 3 ALDAY program for fibromyalgia pain, consisting of three large randomized trials enrolling more than 3,600 subjects in the United States and Europe, failed to meet the primary efficacy endpoint in all three studies; mirogabalin did not demonstrate statistically significant superiority over placebo for reduction in worst daily pain score at week 13 in fibromyalgia, and the fibromyalgia development program was subsequently discontinued. The compound is not approved by the United States Food and Drug Administration or the European Medicines Agency.

    Pharmacokinetically, mirogabalin is rapidly and nearly completely absorbed after oral administration with a time to peak plasma concentration of approximately 1 hour. The compound undergoes limited hepatic metabolism (13 to 20 percent of administered dose) through uridine 5-prime-diphospho-glucuronosyltransferase (UGT) isoforms, with the majority of the dose (61 to 72 percent) excreted unchanged in urine. Renal clearance exceeds glomerular filtration rate, indicating active tubular secretion. Dose adjustment is required in patients with renal impairment. The principal adverse events are somnolence, dizziness, peripheral edema, and weight gain, consistent with the gabapentinoid class but reported at generally lower incidence than pregabalin at comparable analgesic doses in some observational comparisons.

    This monograph reviews the chemistry and structural pharmacology of mirogabalin; the alpha2delta subunit binding characteristics and dissociation kinetics that distinguish the compound from pregabalin and gabapentin; the complete pharmacokinetic record; the preclinical analgesic pharmacology in neuropathic and inflammatory pain models; the clinical evidence base across peripheral neuropathic, central neuropathic, and fibromyalgia indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five alternative analgesic candidates against mirogabalin on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1598Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Bemitil

    Benzimidazole-derived synthetic actoprotector with antihypoxant, antioxidant, and immunomodulatory activity

    A Soviet-developed 2-ethylthiobenzimidazole actoprotector that enhances physical and cognitive performance through genomic activation of protein synthesis, gluconeogenesis enzyme induction, and mitochondrial bioenergetic optimization, distinguished from classical psychostimulants by a non-exhaustive, adaptogenic mechanism that does not increase oxygen consumption or heat production.

    Abstract

    Bemitil (2-ethylthiobenzimidazole hydrobromide; synonyms bemethyl, metaprot, antihot) is the reference compound of the actoprotector drug class, a category of synthetic adaptogens defined by the capacity to enhance physical performance under normal and extreme conditions without increasing oxygen consumption or thermogenesis. Developed in the 1970s at the S.M. Kirov Military Medical Academy in Leningrad by Professor Vladimir Vinogradov and colleagues, bemitil was the first actoprotector to receive state registration in the Soviet Union (1983, registration number 83/654/1) and was subsequently deployed in military, aerospace, and athletic applications including cosmonaut preparation, Soviet national team conditioning for the 1980 Moscow Olympic Games, and operational support during the Afghan campaign and Chernobyl disaster response.

    The molecular pharmacology of bemitil is characterized by genomic activation of RNA and protein synthesis, a property attributable to the structural similarity of the benzimidazole nucleus to the purine bases adenine and guanine. The downstream consequences of this genomic activation include induction of gluconeogenesis enzymes in liver and kidney (accelerating lactate recycling to glucose through the Cori and glucose-alanine cycles), enhanced synthesis of mitochondrial respiratory chain enzymes and structural proteins (increasing ATP production and maintaining oxidative phosphorylation coupling), and upregulation of endogenous antioxidant enzymes including superoxide dismutase, catalase, and glutathione metabolism enzymes. The compound additionally demonstrates antihypoxic activity through maintenance of anaerobic ATP synthesis under oxygen deficit, neuroprotective activity in experimental stroke models, antimutagenic activity against alkylating agent-induced chromosomal aberrations, and immunomodulatory effects through protein synthesis-dependent augmentation of cellular immunity.

    Pharmacokinetics after oral administration are characterized by rapid gastrointestinal absorption (detectable in plasma within 30 minutes), peak effect at 1 to 2 hours with duration of 4 to 6 hours, active hepatic metabolism through cytochrome P450 isoforms CYP1A2, CYP2C9, CYP2D6, and CYP3A4, and urinary elimination predominantly as phase II conjugates. Nine metabolites have been identified in rat urine, with a benzimidazole-acetylcysteine conjugate (molecular formula C12H13N3O3S) representing the most abundant urinary metabolite, consistent with glutathione S-transferase-mediated detoxification. The compound exhibits tissue accumulation on prolonged dosing, with blood concentration increases observed by days 10 to 12 of continuous administration, necessitating cyclical dosing protocols (5 days on, 2 days off) in the registered prescribing information.

    Clinical applications span physical performance enhancement, post-exertional recovery acceleration, treatment of asthenic disorders of diverse etiology (neurasthenia, post-infectious asthenia, postoperative asthenia), and adjunctive therapy in cerebral trauma, meningitis, encephalitis, and cerebrovascular disorders. In a comparative clinical trial of 130 patients with asthenic conditions, bemitil demonstrated superior efficacy to the nootropics piracetam and pyriditol in reducing asthenic symptoms. The compound is generally well tolerated; the principal adverse events are gastrointestinal discomfort, headache, facial flushing, and sleep disturbance when administered in the evening. Contraindications include hypoglycemia, hepatic dysfunction, epilepsy, and pregnancy. The World Anti-Doping Agency placed bemitil on its Monitoring Program in 2018, and detection methods based on UPLC-MS/MS of the parent compound and its glucuronide conjugate in urine have been validated with detection windows extending beyond 30 days post-administration.

    This monograph reviews the chemistry, synthesis, and structural pharmacology of bemitil; the genomic and metabolic mechanisms of action; the pharmacokinetic profile including biotransformation pathways; the preclinical evidence base across performance, neuroprotection, antihypoxic, and antimutagenic endpoints; the clinical evidence in asthenia, physical performance, and rehabilitation; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety; and a comparative assessment of five alternative performance-enhancing or adaptogenic compounds (bromantane, phenylpiracetam, rhodiola rosea extract, levamisole, and sulbutiamine) against bemitil on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1580Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Fish-Oil

    Marine-derived omega-3 polyunsaturated fatty acid complex, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)

    A lipid extract of cold-water marine fish tissue containing the long-chain omega-3 polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid, with established regulatory approval for severe hypertriglyceridemia and a broad but heterogeneous evidence base spanning cardiovascular risk reduction, systemic inflammation, mood disorders, and neurocognitive support.

    Abstract

    Fish oil is a complex lipid extract derived from the tissue of cold-water marine fish species (principally anchovy, sardine, mackerel, herring, and menhaden) and is the predominant dietary and supplemental source of the long-chain omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3). These two fatty acids serve as precursors for specialized pro-resolving mediators (resolvins, protectins, maresins), compete with arachidonic acid for cyclooxygenase and lipoxygenase substrate pools to shift eicosanoid production from pro-inflammatory series-2 prostaglandins and series-4 leukotrienes toward less inflammatory or anti-inflammatory series-3 prostaglandins and series-5 leukotrienes, modulate cell membrane phospholipid composition and lipid raft organization, activate the anti-inflammatory transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma), signal through the G protein-coupled receptor GPR120, and influence ion channel conductance and cardiac electrophysiology. The pharmacological interest in fish oil spans more than five decades, originating with the epidemiological observations of Bang and Dyerberg in Greenland Inuit populations in the early 1970s and progressing through multiple large-scale randomized controlled trials including GISSI-Prevenzione (1999), JELIS (2007), VITAL (2019), REDUCE-IT (2019), and STRENGTH (2020). Prescription omega-3 formulations have received regulatory approval from the United States Food and Drug Administration for the treatment of severe hypertriglyceridemia (triglycerides 500 mg/dL or greater): omega-3-acid ethyl esters (Lovaza, approved 2004), icosapent ethyl (Vascepa, approved 2012), and omega-3-carboxylic acids (Epanova, approved 2014). Icosapent ethyl, a purified EPA ethyl ester, received an expanded FDA indication in 2019 for cardiovascular risk reduction in statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes, based on the REDUCE-IT trial demonstrating a 25 percent relative risk reduction in major adverse cardiovascular events. The STRENGTH trial, which tested a combined EPA and DHA carboxylic acid formulation, was terminated early for futility with no cardiovascular benefit observed, generating ongoing debate regarding the differential efficacy of EPA-only versus EPA plus DHA preparations and the potential confounding role of mineral oil placebo in REDUCE-IT. Fish oil pharmacokinetics are governed by the chemical form of the omega-3 fatty acids (triglyceride, ethyl ester, free fatty acid, or phospholipid), with triglyceride and free fatty acid forms demonstrating superior bioavailability compared to ethyl esters, particularly under low-fat dietary conditions. Absorption requires pancreatic lipase-mediated hydrolysis and micellar solubilization; peak plasma EPA and DHA concentrations are achieved at approximately 5 to 8 hours post-dose, and steady-state tissue incorporation requires 4 to 12 weeks of daily supplementation. The safety profile of fish oil at standard supplemental doses (1 to 4 grams of EPA plus DHA daily) is generally favorable, with the principal adverse events being gastrointestinal discomfort, fishy eructation, and mild prolongation of bleeding time without clinically significant hemorrhage. At pharmacological doses (4 grams daily), meta-analyses of randomized controlled trials have identified a statistically significant increase in the risk of atrial fibrillation (approximately 24 percent relative risk increase), representing the most clinically consequential safety signal in the contemporary evidence base. This monograph reviews the chemical identification and compositional analysis of fish oil; the discovery and development history from the Greenland epidemiology through modern pharmaceutical registration; the molecular pharmacology of EPA and DHA across lipid mediator, transcription factor, membrane, and ion channel mechanisms; pharmacokinetics including formulation-dependent bioavailability; preclinical pharmacology in cardiovascular, inflammatory, and cognitive animal models; the clinical evidence base across cardiovascular, inflammatory, psychiatric, and neurocognitive indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative omega-3 sources (krill oil, algal oil, icosapent ethyl, flaxseed oil, and omega-3-carboxylic acids) against fish oil on five standards (bioavailability, clinical evidence base, safety profile, cost and accessibility, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1562Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Schisandrin B

    Dibenzocyclooctadiene lignan with pleiotropic antioxidant, hepatoprotective, anti-inflammatory, and cytoprotective activity

    A principal bioactive dibenzocyclooctadiene lignan isolated from the fruit of Schisandra chinensis, distinguished by potent Nrf2-dependent antioxidant induction, NF-kB suppression, mitochondrial protective activity, and hepatoprotective efficacy across multiple preclinical models of chemical, ischemic, and metabolic liver injury.

    Abstract

    Schisandrin B (Sch B), also designated gamma-schisandrin, is the most pharmacologically characterized dibenzocyclooctadiene lignan isolated from the dried ripe fruit of Schisandra chinensis (Turcz.) Baill., a climbing vine of the family Schisandraceae with a history of use in traditional Chinese medicine spanning more than two millennia under the name wuweizi (five-flavor berry). Among the more than 30 structurally related lignans present in the Schisandra fruit, Schisandrin B has attracted the greatest research attention owing to a convergence of potent antioxidant, anti-inflammatory, hepatoprotective, cardioprotective, and neuroprotective activities demonstrated across a substantial body of in vitro and in vivo preclinical literature. The compound acts principally through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor and its downstream antioxidant response element (ARE)-dependent gene program, producing upregulation of glutathione S-transferase, heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, superoxide dismutase, and catalase. Concurrently, Schisandrin B suppresses NF-kB nuclear translocation and downstream proinflammatory cytokine expression (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) through inhibition of IkB-alpha degradation and suppression of MAPK cascade phosphorylation at c-Raf, MEK, ERK, JNK, and p38 nodes. Additional characterized mechanisms include enhancement of mitochondrial glutathione antioxidant status and heat shock protein induction, activation of the SIRT1/PI3K/Akt and AMPK/mTOR signaling axes, suppression of ferroptosis through upregulation of SLC7A11, GPX4, and FTH1, and modulation of pregnane X receptor (PXR)-mediated bile acid metabolism. The hepatoprotective activity is the best-validated pharmacological property: Schisandrin B protects against carbon tetrachloride-induced hepatotoxicity, D-galactosamine-induced hepatocyte apoptosis, ischemia-reperfusion liver injury, doxorubicin and pirarubicin-induced hepatotoxicity, acetaminophen hepatotoxicity, cholestatic liver injury, and metabolic-associated fatty liver disease in rodent models, with efficacy demonstrated at oral doses typically in the range of 25 to 100 mg/kg in mice and rats. The compound also exhibits preclinical cardioprotective activity against doxorubicin cardiotoxicity and angiotensin II-induced cardiac fibrosis, and neuroprotective activity against amyloid-beta-induced neuronal dysfunction, scopolamine-induced amnesia, and cisplatin-induced neurotoxicity. Pharmacokinetic characterization in rats demonstrates oral bioavailability of approximately 19 to 55 percent (with sex-dependent variation), extensive hepatic accumulation consistent with its liver-protective profile, a double-peak absorption curve suggestive of enterohepatic circulation, and linear pharmacokinetics across the 10 to 40 mg/kg oral dose range. Schisandrin B is a potent, dose-dependent, noncompetitive inhibitor of CYP3A activity (Ki approximately 16.6 mg/kg in vivo) and inhibits P-glycoprotein-mediated efflux, producing clinically relevant herb-drug interactions with CYP3A substrates including midazolam, tacrolimus, and sirolimus. The compound has not been evaluated in human clinical trials as an isolated entity; all pharmacological and safety characterization derives from preclinical studies and from clinical experience with Schisandra chinensis fruit extracts and the semi-synthetic derivative bifendate (dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate). Preclinical toxicology in dogs has demonstrated dose-dependent plasma accumulation on repeated administration, and in vitro studies at high concentrations have identified paradoxical hepatotoxicity in mouse hepatocytes and macrophages, indicating that the therapeutic window requires careful characterization before clinical translation. This monograph documents the chemistry, stereochemistry, and botanical source of Schisandrin B; the molecular pharmacology across Nrf2, NF-kB, SIRT1, AMPK, and mitochondrial mechanisms; the preclinical pharmacokinetic profile; the comprehensive preclinical evidence base across hepatoprotective, cardioprotective, neuroprotective, anti-inflammatory, and antitumor indications; sourcing and quality verification; reconstitution and handling; stack interactions with emphasis on CYP3A and P-glycoprotein; adverse events and safety signals including dose-dependent hepatotoxicity; and a comparative assessment of five related hepatoprotective or Nrf2-activating compounds against Schisandrin B on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1610Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Procyanidin C1

    B-type proanthocyanidin trimer (oligomeric flavan-3-ol) with senolytic, senomorphic, and multi-target anti-inflammatory activity

    A naturally occurring epicatechin trimer from grape seed extract identified as a dual-mode senotherapeutic agent that selectively eliminates senescent cells at high concentrations while suppressing the senescence-associated secretory phenotype at low concentrations, with demonstrated lifespan extension in mice and emerging preclinical evidence across fibrotic, neurodegenerative, and oncologic indications.

    Abstract

    Procyanidin C1 (PCC1) is a B-type proanthocyanidin trimer composed of three (2R,3R)-(-)-epicatechin units joined by two successive (4beta to 8)-interflavan bonds, with molecular formula C45H38O18 and molecular weight 866.77 g/mol. The compound is a polyphenolic constituent of grape seed extract (GSE), cocoa, cinnamon bark, unripe apple peel, and pine bark, and was first structurally characterized in the 1980s as part of the broader oligomeric proanthocyanidin (OPC) family originally described by Masquelier in 1947. PCC1 remained a minor analytical curiosity within the proanthocyanidin literature until 2021, when a landmark screening study by Xu, Fu, and colleagues, published in Nature Metabolism, identified PCC1 as a potent and selective senotherapeutic agent capable of extending healthspan and lifespan in aged mice through dual-mode activity on senescent cells [1]. At low concentrations (below approximately 50 micromolar), PCC1 acts as a senomorphic agent, suppressing the production of pro-inflammatory senescence-associated secretory phenotype (SASP) factors through inhibition of NF-kappaB signaling without inducing senescent cell death. At higher concentrations (above approximately 100 micromolar), PCC1 transitions to a senolytic mode, selectively inducing apoptosis in senescent cells through a reactive oxygen species (ROS)-dependent mitochondrial dysfunction pathway involving the p53-Puma/Noxa axis, while sparing proliferating and quiescent non-senescent cells. This concentration-dependent functional switch distinguishes PCC1 from most other characterized senolytic agents and provides a pharmacological basis for dose-titrated senotherapeutic intervention.

    The 2021 Nature Metabolism study demonstrated that intermittent administration of PCC1 (20 mg/kg intraperitoneally, biweekly for two months) to aged C57BL/6J mice reduced senescent cell burden across multiple tissues, attenuated age-related physical dysfunction, and extended median remaining lifespan by approximately 64 percent compared to vehicle-treated controls, with no observed systemic toxicity [1]. Subsequent preclinical studies have expanded the evidence base substantially. Zhu, Huang, and colleagues (2024) demonstrated that PCC1 alleviates structural and functional decline in the aged mouse retina through combined senolytic and senomorphic mechanisms [2]. Gan and colleagues (2025) reported that PCC1 alleviates renal fibrosis by promoting apoptosis of senescent renal tubular epithelial cells [3]. Additional preclinical evidence supports activity against skin fibrosis through EGFR inhibition and TGF-beta/SMAD pathway suppression [4], neuroprotection through Nrf2/HO-1 signaling activation [5], endothelial nitric oxide production through PI3K/Akt-dependent eNOS phosphorylation [6], insulin sensitization in adipocytes through AKT-eNOS pathway activation [7], and colon cancer growth inhibition through miR-501-3p/HIGD1A axis modulation [8]. Single-cell profiling has revealed broad geroprotective effects on the hematopoietic immune system, including restoration of B cell and hematopoietic stem cell populations and suppression of senescence-associated inflammatory markers [9].

    Pharmacokinetically, PCC1 shares the absorption limitations characteristic of oligomeric proanthocyanidins: oral bioavailability of trimeric procyanidins is low, with the majority of ingested material reaching the colon intact where it is degraded by gut microbiota into phenylvalerolactones, phenylvaleric acids, and smaller phenolic acid metabolites. Phytosomal formulations have demonstrated 2- to 3-fold improvements in gastrointestinal absorption efficiency. No completed Phase 1 or Phase 2 clinical trials of purified PCC1 have been published as of the most recent monograph revision, though preliminary findings from phytosomal PCC1 formulations have shown reductions in senescence markers in peripheral blood mononuclear cells from elderly individuals. The compound is not approved by any regulatory authority for therapeutic use. It is available as a research-grade preparation from multiple chemical suppliers at greater than 95 percent purity by HPLC. This monograph documents the chemistry, natural sourcing, dual-mode senotherapeutic pharmacology, pharmacokinetics, preclinical evidence base across aging, fibrotic, neurodegenerative, metabolic, and oncologic indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event signal, and a structured comparative assessment of five senolytic candidates against PCC1 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1573Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Suzetrigine

    Selective NaV1.8 voltage-gated sodium channel inhibitor (non-opioid peripheral analgesic)

    A first-in-class, peripherally restricted NaV1.8 sodium channel inhibitor developed by Vertex Pharmaceuticals as a non-opioid analgesic for moderate-to-severe acute pain, distinguished by allosteric binding to voltage-sensing domain 2 and greater than 31,000-fold selectivity over all other sodium channel subtypes.

    Abstract

    Suzetrigine (VX-548; trade name Journavx) is the first selective inhibitor of the NaV1.8 voltage-gated sodium channel to receive regulatory approval, granted by the United States Food and Drug Administration on 30 January 2025 for the treatment of moderate-to-severe acute pain in adults. The compound represents a mechanistically novel analgesic class, acting by allosteric binding to the extracellular S3-S4 loop of voltage-sensing domain 2 (VSD2) of the NaV1.8 channel, where a KKGS amino acid sequence unique to this subtype confers greater than 31,000-fold selectivity over the other nine human voltage-gated sodium channel isoforms. NaV1.8, encoded by the SCN10A gene, is expressed almost exclusively in peripheral nociceptive neurons of the dorsal root ganglia, where it contributes more than 70 percent of the depolarizing current during pain-signaling action potentials. Suzetrigine stabilizes the channel in its closed (resting) state through tonic inhibition that is independent of channel opening frequency, thereby reducing pathological nociceptor hyperexcitability without affecting cardiac, central nervous system, or skeletal muscle sodium channels.

    The compound emerged from a multi-year medicinal chemistry program at Vertex Pharmaceuticals that progressed through the predecessors VX-128 and VX-150 before arriving at VX-548, which demonstrated an in vitro IC50 of 0.68 nanomolar against human NaV1.8 with negligible activity (IC50 greater than 10,000 nanomolar) against all other NaV subtypes. In Phase 2 randomized controlled trials in postoperative bunionectomy and abdominoplasty pain, suzetrigine at a 100 mg loading dose followed by 50 mg every 12 hours produced statistically significant reductions in the time-weighted sum of pain intensity difference over 48 hours (SPID48) compared to placebo (37.8-point and 36.8-point superiority, respectively). In the pivotal Phase 3 NAVIGATE-1 (bunionectomy, N = 1,073) and NAVIGATE-2 (abdominoplasty, N = 1,118) trials, suzetrigine achieved statistically significant superiority over placebo on SPID48 (p = 0.0002 and p < 0.0001, respectively), with analgesic efficacy broadly comparable to hydrocodone/acetaminophen but without opioid-class adverse effects including respiratory depression, sedation, or abuse liability.

    Pharmacokinetics are characterized by oral administration with a time to peak plasma concentration of approximately 3 hours in the fasted state, extensive tissue distribution (volume of distribution approximately 495 liters), 99 percent plasma protein binding, and hepatic metabolism predominantly through CYP3A enzymes to the active metabolite M6-SUZ (3.7-fold less potent than parent compound). The terminal elimination half-life of suzetrigine is 23.6 hours, and that of M6-SUZ is 33.0 hours, supporting twice-daily maintenance dosing. Excretion occurs through both fecal (49.9 percent) and urinary (44.0 percent) routes. The compound is contraindicated with strong CYP3A4 inhibitors and in severe hepatic impairment (Child-Pugh Class C). The most common adverse events in clinical trials were nausea, headache, dizziness, constipation, pruritus, muscle spasms, and rash, all predominantly mild to moderate in severity. No respiratory depression, physical dependence, or abuse potential has been identified in clinical or preclinical assessments.

    This monograph documents the chemistry, structural pharmacology, mechanism of action, comprehensive pharmacokinetics, preclinical and clinical evidence base, regulatory history, sourcing and handling considerations, drug interaction profile, adverse-event signal, and a structured comparative assessment of five alternative analgesic approaches (VX-150, hydrocodone/acetaminophen, pregabalin, celecoxib, and lidocaine 5% patch) against suzetrigine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1576Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Astragaloside IV

    Cycloartane-type triterpenoid saponin glycoside derived from Astragalus membranaceus with pleiotropic anti-inflammatory, antioxidant, and cytoprotective activity

    A cycloartane triterpenoid saponin isolated from Astragalus membranaceus (Huangqi) that modulates NF-kB, PI3K/Akt, and Nrf2/HO-1 signaling to produce cardioprotective, neuroprotective, hepatoprotective, and immunomodulatory effects across a broad preclinical evidence base.

    Abstract

    Astragaloside IV (AS-IV) is a cycloartane-type triterpenoid saponin glycoside and the principal pharmacologically active saponin constituent of Astragalus membranaceus (Huangqi), a botanical drug with over two thousand years of documented use in traditional Chinese medicine for tonification of qi, immune support, and cardiovascular health. The compound, bearing the molecular formula C41H68O14 and a molecular weight of 784.97, consists of a cycloartane aglycone skeleton conjugated to beta-D-glucose and beta-D-xylose sugar moieties. Astragaloside IV has emerged over the past two decades as one of the most extensively investigated natural product saponins in modern pharmacology, with a research literature now spanning cardioprotection, neuroprotection, hepatoprotection, nephroprotection, pulmonary fibrosis attenuation, anti-tumor activity, metabolic syndrome modulation, and telomerase activation through its principal gut-microbial metabolite cycloastragenol.

    The molecular pharmacology of astragaloside IV is characterized by multi-target activity across several canonical signaling cascades. The compound inhibits the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway through suppression of IkB phosphorylation and reduction of nuclear translocation, producing dose-dependent reductions in tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 in activated macrophages and in lipopolysaccharide-challenged animal models. Concurrently, astragaloside IV activates the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) antioxidant response element pathway, upregulating superoxide dismutase, glutathione peroxidase, and catalase expression. The compound modulates the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling axis with context-dependent activation (cardioprotection, neuroprotection) or inhibition (anti-tumor applications), and suppresses the transforming growth factor beta 1 (TGF-beta1)/Smad pathway to attenuate fibrotic remodeling in lung, liver, and kidney tissue. Additional characterized targets include Toll-like receptor 4 (TLR4), the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor gamma (PPARgamma), and glycogen synthase kinase 3 beta (GSK3beta).

    Pharmacokinetics present the principal translational challenge for astragaloside IV. Oral bioavailability in rats is approximately 2.2 to 3.7 percent, and in beagle dogs approximately 7.4 percent, reflecting high molecular weight, poor aqueous solubility, limited intestinal membrane permeability, and predominantly paracellular absorption. The compound undergoes extensive biotransformation by intestinal microflora (principally Bifidobacteria and Lactobacillus species) through sequential deglycosylation to produce cycloastragenol, the aglycone metabolite that is substantially more bioavailable and that mediates telomerase activation through upregulation of human telomerase reverse transcriptase (hTERT) gene expression via the mitogen-activated protein kinase (MAPK) pathway. Plasma elimination half-life in rats after oral administration is approximately 3.8 hours, with highest tissue concentrations in lung and liver.

    The preclinical evidence base is extensive and spans multiple organ systems. In myocardial ischemia-reperfusion models, astragaloside IV at doses of 10 to 80 mg/kg reduces infarct size, improves ejection fraction, and attenuates apoptosis through PI3K/Akt and mitochondrial pathway modulation. In focal cerebral ischemia models, the compound reduces infarct volume and neurological deficit scores through Nrf2/HO-1 activation and NF-kB suppression. In carbon tetrachloride and high-fat-diet hepatotoxicity models, astragaloside IV preserves hepatocyte integrity through antioxidant and anti-inflammatory mechanisms. In diabetic nephropathy models, the compound attenuates glomerular basement membrane thickening and reduces proteinuria. In bleomycin-induced pulmonary fibrosis models, astragaloside IV suppresses collagen deposition through TGF-beta1/Smad pathway inhibition.

    Clinical evidence in humans remains limited. Safety data from Phase 1 studies of an intravenous astragaloside IV preparation in healthy Chinese volunteers demonstrated tolerability at single doses of 200 to 600 milliliters (0.09 mg/mL) and multiple daily doses over one week without toxic reactions or plasma accumulation. Astragalus membranaceus extract preparations containing astragaloside IV as a standardized marker compound are registered in the Chinese Pharmacopoeia and are widely used in clinical practice in China, Japan, and the Republic of Korea for cardiovascular, hepatic, and immune-support indications. The telomerase-activating metabolite cycloastragenol is the active principle of the commercial nutraceutical TA-65, which has produced positive telomere-lengthening results in randomized controlled trials in middle-aged and older adults.

    This monograph documents the chemistry, biosynthesis, and structural characterization of astragaloside IV; the multi-target molecular pharmacology across NF-kB, Nrf2, PI3K/Akt, TGF-beta1/Smad, TLR4, and telomerase pathways; the pharmacokinetic profile including the critical gut-microbial biotransformation to cycloastragenol; the preclinical evidence base across cardiovascular, neurological, hepatic, renal, pulmonary, metabolic, and oncological models; the limited clinical evidence; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety data; and a comparative assessment of five structurally or functionally related triterpenoid saponins against astragaloside IV on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1612Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Canagliflozin

    Selective sodium-glucose cotransporter 2 (SGLT2) inhibitor with secondary SGLT1 inhibitory activity

    A thiophene-containing C-glucoside developed by Mitsubishi Tanabe Pharma and licensed to Janssen as the first SGLT2 inhibitor approved in the United States, distinguished by dual SGLT2/SGLT1 inhibition and landmark cardiovascular and renal outcomes evidence from the CANVAS Program and CREDENCE trial.

    Abstract

    Canagliflozin is a potent, orally bioavailable inhibitor of the sodium-glucose cotransporter 2 (SGLT2) and the first agent of its class to receive United States Food and Drug Administration approval for the treatment of type 2 diabetes mellitus. The compound acts through an insulin-independent mechanism by blocking the reabsorption of filtered glucose in the proximal tubule of the kidney, producing sustained glycosuria, reduction in plasma glucose, modest body weight loss, and reduction in systolic blood pressure. Structurally, canagliflozin is a C-glucoside bearing a thiophene ring in the aglycone region, conferring metabolic stability against glucosidase cleavage and contributing to oral bioavailability of approximately 65 percent. The inhibition constant for human SGLT2 is approximately 4.2 nM, with approximately 160-fold to 250-fold selectivity over SGLT1 (Ki approximately 710 to 910 nM), a selectivity ratio that permits modest intestinal SGLT1 inhibition at the 300 mg clinical dose, contributing to postprandial glucose lowering through delayed intestinal glucose absorption [1, 2].

    The compound was discovered at Mitsubishi Tanabe Pharma through systematic optimization of C-glucoside scaffolds for SGLT2 potency, metabolic stability, and oral pharmacokinetics [1]. Janssen Pharmaceuticals obtained development and commercialization rights through a licensing agreement and advanced canagliflozin through a comprehensive Phase 3 program (nine controlled studies, approximately 10,285 subjects) culminating in FDA approval on 29 March 2013 under the trade name Invokana [3, 4]. The compound was subsequently approved by the European Medicines Agency in November 2013 and in multiple additional jurisdictions. A fixed-dose combination with metformin (Invokamet) was approved in 2014.

    The clinical evidence base for canagliflozin extends substantially beyond glycemic control. The CANVAS Program (Canagliflozin Cardiovascular Assessment Study and CANVAS-R; N = 10,142; mean follow-up 188.2 weeks), published by Neal et al. in the New England Journal of Medicine in 2017, demonstrated a statistically significant 14 percent reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (hazard ratio 0.86; 95 percent confidence interval 0.75 to 0.97) [5]. The CREDENCE trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; N = 4,401; median follow-up 2.62 years), published by Perkovic et al. in the New England Journal of Medicine in 2019, demonstrated a 30 percent reduction in the primary composite of end-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death (hazard ratio 0.70; 95 percent confidence interval 0.59 to 0.82), establishing canagliflozin as the first SGLT2 inhibitor with a dedicated positive renal outcomes trial [6].

    Pharmacokinetics are characterized by rapid oral absorption (time to peak 1 to 2 hours), dose-proportional exposure across a wide range (50 to 1600 mg), steady-state attainment within 4 to 5 days, and predominant elimination through hepatic O-glucuronidation by UGT1A9 and UGT2B4, producing two inactive metabolites (M5 and M7) [7]. The terminal elimination half-life is approximately 10.6 to 13.1 hours at steady state, supporting once-daily dosing. Approximately 60 percent of the administered dose is recovered in feces and 33 percent in urine. Clinically significant drug-drug interactions are limited; UGT enzyme inducers (rifampin, phenytoin, ritonavir) reduce canagliflozin exposure and may require dose adjustment.

    The safety profile includes class-related adverse events: genital mycotic infections (principally vulvovaginal candidiasis in women and balanitis in men; occurring in approximately 10 to 12 percent of patients), urinary tract infections, volume depletion events related to osmotic diuresis, and euglycemic diabetic ketoacidosis (rare but clinically significant). The CANVAS Program identified a signal for increased lower-extremity amputations (6.3 versus 3.4 per 1,000 patient-years; hazard ratio 1.97), predominantly at the toe and metatarsal level, prompting an FDA boxed warning in 2017 that was subsequently removed in 2020 after additional data, including the CREDENCE trial, did not confirm the excess risk at a comparable magnitude [5, 8]. Bone fracture risk was identified in CANVAS but not confirmed in CREDENCE. Fournier gangrene (necrotizing fasciitis of the perineum) has been reported rarely across the SGLT2 inhibitor class.

    This monograph documents the chemistry, synthesis, and structure-activity relationships of canagliflozin; the molecular pharmacology of SGLT2 and SGLT1 inhibition; the comprehensive human pharmacokinetic record; preclinical pharmacology in animal models of diabetes and kidney disease; the clinical evidence base across glycemic, cardiovascular, and renal outcomes; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; adverse-event signal including the amputation and ketoacidosis findings; and a structured comparative assessment of five SGLT2 inhibitor alternatives (dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin, and bexagliflozin) against canagliflozin on five competency standards: novelty, effect size, promising potential, side-effect profile, and overall validation.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1603Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.